Occupational Therapists in White Hall, AR Accepting Medicare

3 Occupational Therapists found. Showing 1 - 3

Mr. Cedric D Watts, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 7500 Dollarway Rd, Suite 301, White Hall, AR 71602 Phone: 870-329-9626    Fax: 870-534-5912

Mrs. Shannon Perry Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 9209 Dollarway Rd, White Hall, AR 71602 Phone: 870-247-0800

Haley Dianne Burns Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 141 Chipmunk Dr, White Hall, AR 71602 Phone: 501-205-6143    Fax: 501-694-1609

News Archive

Study findings may help shed light on cause of systemic sclerosis

Americans and Norwegians with systemic sclerosis had higher levels of bacteria that can cause inflammation and lower levels of bacteria that are believed to protect against inflammation compared with healthy people, according to a new study by researchers from UCLA and Oslo University.

Exercise for type 2 diabetes mellitus

Exercise, dietary changes and medication have long been the cornerstones of managing type 2 diabetes. But few studies examine how exercise actually benefits these patients.

Kenyan AIDS activists protest over unspent PEPFAR funds

"More than 400 Kenyan AIDS activists have demonstrated in the capital, Nairobi, demanding that the U.S. President's Emergency Plan for AIDS Relief release some $500 million for HIV programs in Kenya that is stuck in the pipeline," PlusNews reports.

Dementia patients treated with neuroleptic drugs instead of anti-dementia medication: Study

Demented patients are often treated nonspecifically with psychoactive medications. Neuroleptic drugs are given even when they are not specifically indicated, as Tomislav Majic and his colleagues from the Charité Hospital, Berlin, show in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2010; 107[18]: 320-7).

Hepatic encephalopathy drug XIFAXAN 550 mg tablets receives FDA marketing approval

Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration has granted marketing approval for XIFAXAN 550 mg tablets for reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. HE is a serious disorder caused by chronic liver failure, resulting in cognitive, psychiatric and motor impairments. This approval was supported by findings from the largest randomized trial of maintenance therapy in HE conducted to date, which assessed the efficacy and safety of XIFAXAN 550 mg tablets and demonstrated a statistically significant and clinically meaningful reduction in the risk of overt HE recurrence.

Read more Medical News

› Verified 2 days ago